Tag: MRD

Early prognosis prediction in acute myeloid and acute lymphoid Leukaemia patients by cell free DNA (cfDNA) Concentration Ratios

1Indian Council of Medical Research (ICMR), India 2Vardhman Mahavir Medical College & Safdarjung Hospital, India The final, formatted version of the article will be published soon. Notify me Receive an email when it is updated You just subscribed to receive the final…

Continue Reading Early prognosis prediction in acute myeloid and acute lymphoid Leukaemia patients by cell free DNA (cfDNA) Concentration Ratios

How MRD Testing Can Help

MRD testing is incredibly valuable in informing clinical decision-making in the treatment of lymphoid malignancies, and its adoption by all oncologists is crucial in the era of precision medicine. During my 10 plus years of practicing medicine, I have seen the blood cancer treatment landscape transform, as the development of…

Continue Reading How MRD Testing Can Help

UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Faculty and trainees from the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) joined the world’s largest hematology community to discuss the latest updates in blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held December 9-12, 2023 in San Diego and online. At the meeting,…

Continue Reading UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Darzalex Faspro combo of help with multiple myeloma diagnosis, transplant

Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to significantly better outcomes for people who are newly diagnosed with multiple myeloma and transplant eligible. That’s according to four-year data from the Phase 3 PERSEUS (NCT03710603) clinical…

Continue Reading Darzalex Faspro combo of help with multiple myeloma diagnosis, transplant

Subcutaneous Daratumumab is Safe and Tolerable in Multiple Myeloma

Bone marrow aspirate cytology of multiple myeloma: ©David A Litman – stock.adobe.com Findings from the phase 3 PERSEUS study (NCT03710603) presented at the 2023 ASH Annual Meeting showed that subcutaneous daratumumab (Darzalex) followed by autologous stem cell transplant (ASCT) and daratumumab, bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) consolidation and…

Continue Reading Subcutaneous Daratumumab is Safe and Tolerable in Multiple Myeloma

Seven precision medicine companies worth keeping an eye on

Precision medicine is an approach to tailoring treatments based on people’s genetic makeup, lifestyles and environment. These targeted interventions can tackle diseases like cancer, neurological as well as metabolic diseases. The global market value of the precision medicine industry, encompassing many companies, crossed 70 billion last year, and is expected…

Continue Reading Seven precision medicine companies worth keeping an eye on

Increasing Widespread Accessibility of Molecular Testing for Oncology Research

Advancements in cancer diagnostics and monitoring have revolutionized the way we understand and treat this complex disease. The advent of molecular technologies for analyzing nucleic acids has made it possible to detect, analyze and monitor cancer more precisely and sensitively than ever before. Furthermore, it has made noninvasive liquid biopsy…

Continue Reading Increasing Widespread Accessibility of Molecular Testing for Oncology Research

Measurable Residual Disease-Guided Therapy Promising in CLL

SAN DIEGO — In untreated chronic lymphocytic leukemia (CLL), patients who received ibrutinib plus venetoclax for a duration determined by disease characteristics rather than a fixed schedule had significantly better progression-free and overall survival compared with conventional chemoimmunotherapy, a new phase 3 analysis shows. The targeted therapy combination was also…

Continue Reading Measurable Residual Disease-Guided Therapy Promising in CLL

Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia

Rasche M, Zimmermann M, Borschel L, Bourquin J, Dworzak M, Klingebiel T, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32:2167–77. Article  PubMed  PubMed Central  Google Scholar  Manola KN. Cytogenetics of pediatric acute…

Continue Reading Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia

New personalized therapy improves survival for patients with CLL leukemia, phase 3 trial finds

Credit: Pixabay/CC0 Public Domain Personalized treatment for the most common form of adult leukemia helps patients survive for longer and stay in remission, a phase 3 trial has found. The trial, by the University of Leeds, is published in the New England Journal of Medicine and has been presented at…

Continue Reading New personalized therapy improves survival for patients with CLL leukemia, phase 3 trial finds

New Data Presented at ASH from the Phase 3 GLOW Study Show

Additional data from the Phase 2 CAPTIVATE study, show 82 percent of patients with previously untreated chronic lymphocytic leukaemia (CLL) treated with fixed-duration ibrutinib plus venetoclax did not need next-line treatment at 54 months1,2 BEERSE, BELGIUM, Dec. 11, 2023 (GLOBE NEWSWIRE) — The Janssen Pharmaceutical Companies of Johnson & Johnson…

Continue Reading New Data Presented at ASH from the Phase 3 GLOW Study Show

Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL

Treatment with odronextamab (REGN1979) led to an objective response rate (ORR) of 52%, with encouraging progression-free (PFS) and overall survival (OS) among complete responders in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a final analysis of the phase 2 ELM-2 trial (NCT03888105) presented at…

Continue Reading Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL

Pilot study uses circulating tumor DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma (DLBCL)

MAESTRO-Pool, a means of detecting circulating tumor DNA (ctDNA), could be sensitive and selective enough to help guide treatment decisions. Dana-Farber Cancer Institute investigators, in collaboration with researchers from the Broad Institute, demonstrated in a retrospective clinical study that a novel test for ctDNA was more sensitive and more specific…

Continue Reading Pilot study uses circulating tumor DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma (DLBCL)

Updated Odronextamab Data from Relapsed/Refractory Diffuse

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exploratory data from the…

Continue Reading Updated Odronextamab Data from Relapsed/Refractory Diffuse

Sanofi – Sarclisa Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant -December 08, 2023 at 09:18 am EST

PARIS – The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free survival (PFS) compared with VRd alone in transplant-ineligible patients with…

Continue Reading Sanofi – Sarclisa Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant -December 08, 2023 at 09:18 am EST

NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response

FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR� assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio Breast Cancer Symposium (SABCS). RaDaR data will be…

Continue Reading NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response

Adela Presents Data Demonstrating Strong Prognostic Prediction Capabilities in Lung Cancer at the 2023 Multidisciplinary Thoracic Cancers Symposium

Individuals with higher quantities of cancer signal from cell-free DNA (cfDNA) prior to treatment had a significantly increased likelihood of recurrence post-treatment Adela’s tissue-agnostic platform shows potential to inform treatment decisions by predicting prognosis FOSTER CITY, Calif., Nov. 30, 2023 /PRNewswire/ — Adela, Inc., an innovator in blood testing for minimal…

Continue Reading Adela Presents Data Demonstrating Strong Prognostic Prediction Capabilities in Lung Cancer at the 2023 Multidisciplinary Thoracic Cancers Symposium

Bioinformatics – Intern at Exact Sciences

Position Overview/Summary Exact Sciences is seeking a Bioinformatics intern to help optimize and improve the algorithms in the MRD program. Essential Duties Include, but are not limited to, the following: Assist with routine operation of our sequencing bioinformatic analysis pipeline. Create and optimize new and existing bioinformatics pipelines. Perform analysis…

Continue Reading Bioinformatics – Intern at Exact Sciences

Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study

Genetic characterization For risk stratification and identification of genetic aberrations suitable as MRD targets, diagnostic material from 133 children with primary AML was examined (see “Methods” and Supplementary Table 3). The presence of selected fusion genes and mutations was prospectively investigated using (q)RT-PCR and sequencing. A primary genetic aberration was found…

Continue Reading Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study

HPV Tumor DNA May Offer Early Warning of Cervical Cancer at High Risk of Relapse

HPV-positive circulating tumor (ct)DNA after chemoradiation (CRT) for cervical cancer had an independent association with worse outcomes, suggesting potential as a biomarker to guide decision-making, a prospective, multicenter study showed. Patients with detectable HPV ctDNA at the end of CRT had significantly worse 2-year progression-free survival as compared with undetectable…

Continue Reading HPV Tumor DNA May Offer Early Warning of Cervical Cancer at High Risk of Relapse

New assay could revolutionize detection and treatment of acute myeloid leukemia

Design of droplet digital PCR (ddPCR) assay. A: Schematic of ddPCR assay. Primers spanned the fusion break points (KMT2A-AF4 depicted). Nested fluorescently labeled probes recognized unique sequences in KMT2A (FAM) and the fusion partner AFF1-AF4 (HEX). B: Example ddPCR result depicting double-positive droplets containing cDNA with an oncogenic KMT2A fusion…

Continue Reading New assay could revolutionize detection and treatment of acute myeloid leukemia

Maintenance Ibrutinib Improves Efficacy in MCL

The primary end point for this study was to determine the 3-year PFS rate from the beginning of ibrutinib maintenance treatment. Secondary end points were to analyze toxicity, and assess partial response and CR rates. Results from the phase 2 NU 14H06 study (NCT02242097) demonstrated efficacy in using ibrutinib (Imbruvica)…

Continue Reading Maintenance Ibrutinib Improves Efficacy in MCL

Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

NATICK, Mass., Nov. 8, 2023 /PRNewswire/ — Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City,…

Continue Reading Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE

Kitted assays for clinical laboratories streamline the detection of challenging genes and variants to improve results for underrepresented populations MINNEAPOLIS , Nov. 2, 2023 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to cystic fibrosis variant detection, cancer…

Continue Reading ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE

Accepted votca 2022.1-2 (source) into unstable

—–BEGIN PGP SIGNED MESSAGE—– Hash: SHA512 Format: 1.8 Date: Sun, 29 Oct 2023 11:59:12 -0700 Source: votca Architecture: source Version: 2022.1-2 Distribution: unstable Urgency: medium Maintainer: Debichem Team <debichem-de…@lists.alioth.debian.org> Changed-By: Nicholas Breen <nbr…@debian.org> Closes: 1042660 Changes: votca (2022.1-2) unstable; urgency=medium . [ Nicholas Breen ] * sphinx-7-styles.patch: Build with newer…

Continue Reading Accepted votca 2022.1-2 (source) into unstable

Transgenic expression in zebrafish embryos with an intact chorion by electroporation and microinjection

Biotechnol Rep (Amst). 2023 Dec; 40: e00814. Nusrat Tazin aDepartment of Electrical and Computer Engineering, University of Utah, Salt Lake City, UT, USA Christopher Jordon Lambert bDepartment of Mechanical Engineering, University of Utah, Salt Lake City, Utah, USA Raheel Samuel bDepartment of Mechanical Engineering, University of Utah, Salt Lake City,…

Continue Reading Transgenic expression in zebrafish embryos with an intact chorion by electroporation and microinjection

Personalis start early access program for cancer detection blood test

NeXT Personal Dx has a specificity exceeding 99.9% and can detect down to 1×10-⁶ tumour fraction. Credit: ArtemisDiana / Shutterstock. Personalis has launched the Early Access Program for NeXT Personal Dx, a liquid biopsy laboratory-developed test for detecting molecular residual disease (MRD) and recurrence in cancer. NeXT Personal Dx is…

Continue Reading Personalis start early access program for cancer detection blood test

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests // Combined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion diagnostic solutions based on PCR, digital PCR (using the QIAcuity system), and NGS // Future projects may include advanced analysis and accessibility…

Continue Reading QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

Global DNA Sequencing Market 2023 Business Growth, Competitive

DNA Sequencing Market The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 The Business Research Company’s DNA Sequencing Global Market Report 2023 identifies increasing prevalence of cancer as the major driver for the DNA Sequencing…

Continue Reading Global DNA Sequencing Market 2023 Business Growth, Competitive

Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study -October 21, 2023 at 04:25 am EDT

Personalis, Inc. announced the presentation of initial findings from its work with the TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management. Thealis NeXT Personal cancer assay, created to detect and monitor residual and recurrent disease (MRD), demonstrated significantly improved detection…

Continue Reading Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study -October 21, 2023 at 04:25 am EDT

Predicine announces six studies showcasing MRD and liquid

HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) — Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. The company will present six compelling poster studies, unveiling the future of liquid biopsy solutions. These poster presentations will…

Continue Reading Predicine announces six studies showcasing MRD and liquid

Introduction to cfDNA; The Difference Between cfDNA and ctDNA

cfDNA is a DNA fragment released by various cells into the blood or other body fluids. cfDNA can serve as a biomarker for various diseases, especially cancer, reflecting the genomic variation and gene expression of tumor cells. cfDNA analysis has become a promising method for cancer diagnosis, treatment selection, and…

Continue Reading Introduction to cfDNA; The Difference Between cfDNA and ctDNA

ctDNA Pushes Its Prognostic Role in Large Cell Lymphomas

Large cell lymphomas are curable, but aggressive. Despite that, some 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will develop relapsing/refractory disease.1 To ensure a cure, physicians typically use CT and positron emission tomography-computedtomography (PET-CT) scans to look for signs of minimum residual disease (MRD) when treatment…

Continue Reading ctDNA Pushes Its Prognostic Role in Large Cell Lymphomas

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma | Small Molecules

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma Details Category: Small Molecules Published on Saturday, 30 September 2023 10:46 Hits: 112 CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone …

Continue Reading AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma | Small Molecules

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone Results are being presented at the International Myeloma Society Annual Meeting in Athens, Greece AbbVie will discuss the data with health authorities in the near future to further understand the…

Continue Reading AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

Alginate Beads as a Tool for Production of Human IPSCs

Introduction There are several promising applications for human-induced pluripotent stem cells (IPSCs), including cell replacement therapies, tissue engineering, and high-throughput toxicological and pharmacological screening.1 The scalable expansion and differentiation of IPSCs are demanding and inefficient; in particular, they commonly require the use of two-dimensional (2D) cultures.2 Data on stem cell…

Continue Reading Alginate Beads as a Tool for Production of Human IPSCs

Illumina Oncology – Whole-genome sequencing (WGS) in acute myeloid leukemia (AML)

Illumina Oncology – Whole-genome sequencing (WGS) in acute myeloid leukemia (AML) 26 September 2023 Eric Duncavage, MD, explains how patients with AML can benefit from whole-genome sequencing testing at diagnosis and after treatment for minimal or measurable residual disease (MRD) assessment. Dr. Duncavage is the director of the sections of…

Continue Reading Illumina Oncology – Whole-genome sequencing (WGS) in acute myeloid leukemia (AML)

Mission Bio Announces and Launches Single-Cell Measurable Residual Disease (MRD) Assay –

What You Should Know: Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay. The company designed the scMRD AML Multiomics Assay to bring unprecedented resolution to disease relapse and recurrence in acute myeloid leukemia (AML), demonstrating the…

Continue Reading Mission Bio Announces and Launches Single-Cell Measurable Residual Disease (MRD) Assay –

Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

Circulating tumor DNA(ctDNA) status at the time of postoperative minimal residual disease (MRD) is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer (CRC). Standard management calls for adjuvant chemotherapy for all patients following surgical resection; however, investi- gators have sought to refine…

Continue Reading Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

Myriad Genetics, Memorial Sloan Kettering collaborate on MRD testing for breast cancer

Myriad Genetics is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to study the use of Myriad’s minimal residual disease (MRD) testing platform in predicting breast cancer treatment response. The platform is a tumor-informed high-definition assay that monitors circulating tumor DNA (ctDNA) levels via whole-genome sequencing. The partners will be…

Continue Reading Myriad Genetics, Memorial Sloan Kettering collaborate on MRD testing for breast cancer

ctDNA May Play Role in Large Cell Lymphoma Detection

Currently, CT/PET scans are primarily used for staging, response assessment, and surveillance, according to Mark J. Roschewski, MD. The use of circulating tumor DNA (ctDNA) may supplement imaging scans, effectively aiding in detecting active large cell lymphoma in patients near the end of treatment, according to Mark J. Roschewski, MD…

Continue Reading ctDNA May Play Role in Large Cell Lymphoma Detection

Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma

Testing for measurable residual disease (MRD) in persons with plasma cell myeloma (PCM) after therapy correlates with therapy outcomes including progression-free survival (PFS) and survival (reviewed in refs. [1, 2]). Most MRD-testing in this setting uses multi-parameter flow cytometry (MPFC) but prediction accuracy is imperfect with C-statistics of only about…

Continue Reading Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma

Dr Shah on Unmet Needs in the Treatment of Older Patients with DLBCL

Nirav N. Shah, MD, associate professor, Froedtert & Medical College of Wisconsin, discusses the rationale for launching a phase 2 trial (NCT03943901) of split-dose R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) in older patients with diffuse large B-cell lymphoma (DLBCL), touching on the unmet needs seen in the treatment…

Continue Reading Dr Shah on Unmet Needs in the Treatment of Older Patients with DLBCL

Dr Shah on the Investigation of Split-Dose R-CHOP in DLBCL

Nirav N. Shah, MD, associate professor, Froedtert & Medical College of Wisconsin, discusses primary outcomes from a phase 2 trial (NCT03943901) investigating split-dose R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) in older patients with diffuse large B-cell lymphoma (DLBCL). Elderly, unfit, or frail patients with DLBCL often have decreased…

Continue Reading Dr Shah on the Investigation of Split-Dose R-CHOP in DLBCL

Building A Comprehensive Whole-Genome Cancer Monitoring Platform

C2i Genomics is the first company to develop the most comprehensive whole-genome monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA. Pulse 2.0 interviewed C2i Genomics’ co-founder and CEO Ezra Sofer to learn more. Ezra Sofer’s Background Sofer focuses on leading the…

Continue Reading Building A Comprehensive Whole-Genome Cancer Monitoring Platform

Watchmaker Genomics Announces Co-Exclusive License to Disruptive DNA Methylation Technology and Strategic Supply Agreements with Exact Sciences

Agreements Will Help Drive Greater Accuracy of Epigenetic Information for the Early Detection of Cancer BOULDER, Colo., August 30, 2023 – Watchmaker Genomics, a supplier of innovative products for molecular analysis, today announced a multi-year, co-exclusive agreement with Exact Sciences Corporation, a leading provider of cancer screening and diagnostic tests,…

Continue Reading Watchmaker Genomics Announces Co-Exclusive License to Disruptive DNA Methylation Technology and Strategic Supply Agreements with Exact Sciences

Geneos Therapeutics’ Groundbreaking Cancer Vaccine Trial Yields Remarkable Results: Complete Response Achieved in 8 out of 34 Patients with Advanced Liver Cancer

PLYMOUTH MEETING, PA — Geneos Therapeutics, a clinical-stage biotherapeutics company, recenlty announced updated data from GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study in second-line advanced hepatocellular carcinoma (HCC). Previously, Geneos reported three patients to have achieved a complete response (CR) and a fourth patient to be cancer-free, whose…

Continue Reading Geneos Therapeutics’ Groundbreaking Cancer Vaccine Trial Yields Remarkable Results: Complete Response Achieved in 8 out of 34 Patients with Advanced Liver Cancer

Genomics Market Size, Share, Growth, Outlook 2023-2030

PRESS RELEASE Published August 22, 2023 “Genomics Market – DataM Intelligence” Genomics Market is estimated to grow at a CAGR of 18.7% during the forecast period 2023-2030 Market Overview: The branch of biology known as genomics focuses on understanding an organism’s entire gene or genetic makeup (DNA). It entails deciphering…

Continue Reading Genomics Market Size, Share, Growth, Outlook 2023-2030

Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response

  –By RECIST1.1, Three Complete Responses and Seven Durable Partial Responses Achieved to Date– –Three of the Seven Patients With Durable Partial Responses, and One With Stable Disease, Have Now Achieved Complete Molecular Response By Ultrasensitive ctDNA Analysis–  –No Serious Adverse Events Related…

Continue Reading Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response

AI cancer startup collaborates with top Israeli hospital

Cancer detection startup C2i Genomics is teaming up with Tel Aviv Sourasky Medical Center, also known as Ichilov Hospital, to enable early detection of recurring cancer using a cloud-based AI solution. C2i Genomics’ whole genome minimal residual disease (MRD) testing improves cancer detection and monitoring by uploading blood test data…

Continue Reading AI cancer startup collaborates with top Israeli hospital

Epcoritamab: First Approval | SpringerLink

AbbVie. EPKINLY™ (epcoritamab-bysp) approved by U.S. FDA as the first and only bispecific antibody to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [media release]. 19 May 2023. www.abbvie.com. Genmab US, Inc. EPKINLY™ (epcoritamab-bysp) injection, for subcutaneous use: US prescribing information. 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324Orig1s000lbl.pdf. Accessed 21 June…

Continue Reading Epcoritamab: First Approval | SpringerLink

Minimal Residual Disease Testing Market to hit USD 4.1

Selbyville, Delaware, Aug. 14, 2023 (GLOBE NEWSWIRE) — Minimal Residual Disease Testing Market size is expected to be worth USD 4.1 billion by 2032. The global minimal residual disease (MRD) testing market will experience significant expansion by 2032 as precision medicine revolutionizes cancer diagnosis and treatment. MRD testing has emerged…

Continue Reading Minimal Residual Disease Testing Market to hit USD 4.1

NCCN B-cell lymphoma welcomes another update! New treatment options for diffuse large B-cell lymphoma!

The content of the guide interpretation column is continuously updated every week, and popular & new guides are selected for interpretation for everyone to learn. The NCCN clinical practice guidelines for B-cell lymphoma ushered in the latest version 2023.V4. Compared with the 2023.V3 version, this updated version mainly involves the…

Continue Reading NCCN B-cell lymphoma welcomes another update! New treatment options for diffuse large B-cell lymphoma!

Illumina, Inc. (NASDAQ:ILMN) Q2 2023 Earnings Call Transcript

Illumina, Inc. (NASDAQ:ILMN) Q2 2023 Earnings Call Transcript August 10, 2023 Operator: Good day, ladies and gentlemen, and welcome to the Second Quarter 2023 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be…

Continue Reading Illumina, Inc. (NASDAQ:ILMN) Q2 2023 Earnings Call Transcript

Circulating Tumor DNA and MRD Assessment in Colorectal Cancer

Transcript: Tanios S. Bekaii-Saab, MD: Moving beyond colorectal cancer, can you talk at a high level about other areas where the field of MRD [minimal residual disease] assessment is being investigated? Joleen Hubbard, MD: We saw multiple abstracts in different malignancies at ASCO [American Society of Clinical Oncology Annual Meeting]….

Continue Reading Circulating Tumor DNA and MRD Assessment in Colorectal Cancer

NeoGenomics secures Medicare coverage for breast cancer blood test

NeoGenomics has secured U.S. reimbursement for its RaDaR assay in breast cancer patients through the Molecular Diagnostics Services Program (MolDx). RaDaR tests for up to 48 tumor-specific variants in cell-free DNA in blood plasma samples. NeoGenomics has designed the assay, which it sells as a laboratory-developed test in the U.S.,…

Continue Reading NeoGenomics secures Medicare coverage for breast cancer blood test

Leveraging the Full Potential of Sensitive Circulating Tumor DNA Analyses

Credit: eldemir/Getty Images Sponsored content brought to you by Liquid biopsy analyses have redefined the constraints of cancer research, offering a noninvasive approach for the detection and monitoring of mutations critical to characterizing disease status. While pioneered primarily in the field of hematological oncology, liquid biopsy is a highly promising…

Continue Reading Leveraging the Full Potential of Sensitive Circulating Tumor DNA Analyses

Osimertinib Is Considered Standard of Care for Patients With Resected EGFR+ NSCLC

In light of the overall survival (OS) analysis from the phase 3 ADAURA trial (NCT02511106), lung cancer specialists consider osimertinib (Tagrisso) to be the established standard-of-care treatment option for patients with resected EGFR-mutant non–small-cell lung cancer (NSCLC), according to a presentation by Masahiro Tsuboi, MD, at the 24th Annual International Lung Cancer…

Continue Reading Osimertinib Is Considered Standard of Care for Patients With Resected EGFR+ NSCLC

Myeloid Cancer Panel cfDNA Reference Standard

The Myeloid Cancer Panel cfDNA reference standard is a well-characterized cell line-derived control which contains 15 clinically-relevant variants across 14 genes. This cell-free DNA reference material allows labs to perform reliable and cost-effective validations of myeloid cancer liquid biopsy assays. QC pipelines are supported by controls manufactured under ISO:13485 with…

Continue Reading Myeloid Cancer Panel cfDNA Reference Standard

PacBio Begins Commercialization of the Onso Short-Read Sequencing System

The Onso Platform Delivers Extraordinary Accuracy Which Creates New Possibilities for Research and Translational Sequencing Applications MENLO PARK, Calif., Aug. 2, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced that customer shipments of Onso short-read sequencing instruments will commence today. As previously announced,…

Continue Reading PacBio Begins Commercialization of the Onso Short-Read Sequencing System

Natera Sues NeoGenomics for Patent Infringement

NEW YORK – Natera announced on Monday that it has filed a patent infringement lawsuit against NeoGenomics related to the latter’s Radar molecular residual disease (MRD) assay. The lawsuit, filed in the North Carolina Federal District Court, alleges that the Radar assay infringes Natera’s patents 11,519,035 and 11,530,454, both of…

Continue Reading Natera Sues NeoGenomics for Patent Infringement

Detection of low-frequency mutations in clinical samples by increasing mutation abundance via the excision of wild-type sequences

Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532 (1988). Article  CAS  PubMed  Google Scholar  Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593, 405–410 (2021). Diaz, L. A. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol….

Continue Reading Detection of low-frequency mutations in clinical samples by increasing mutation abundance via the excision of wild-type sequences

NeoGenomics (NEO) Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

NeoGenomics, Inc. (NASDAQ: NEO) announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR� assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection. Following this decision, effective as of March 24, 2023, the RaDaR assay is now covered for fee-for-service Medicare…

Continue Reading NeoGenomics (NEO) Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options

SAN DIEGO, July 25, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio…

Continue Reading Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options

ctDNA vs cfDNA for Assessing MRD

Transcript: Tanios S. Bekaii-Saab, MD: Aparna, this is a small emerging field of assessing minimal residual disease and circulating tumor DNA [ctDNA], and we also hear circulating cell-free DNA [cfDNA]. I got a lot of questions from the community. What is ctDNA versus cfDNA? Perhaps you can give us some…

Continue Reading ctDNA vs cfDNA for Assessing MRD

Bioinformatics Scientist 1 – Liquid Biopsy / Collaborations – Fremont

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000…

Continue Reading Bioinformatics Scientist 1 – Liquid Biopsy / Collaborations – Fremont

Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer | BMC Medicine

Patient characteristics and tumor-informed methylation analysis Of the 387 consecutive patients with suspected NSCLC, a total of 195 patients (stage I-II 165, 84.6%) were included in the MEDAL cohort. The clinicopathological features of the MEDAL cohort were comparable to that of the independent DYNAMIC cohort [2] (Table 1; Additional file…

Continue Reading Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer | BMC Medicine

Sorafenib Maintenance After Transplant Deemed Standard Care for FLT3-ITD AML

Updated phase 3 data support sorafenib maintenance after allogeneic transplant as standard care for patients with FLT3-ITD acute myeloid leukemia (AML), according to researchers.1 Sorafenib maintenance improved overall survival (OS), leukemia-free survival (LFS), and other outcomes in this 5-year update of a phase 3 trial. Researchers reported these findings in…

Continue Reading Sorafenib Maintenance After Transplant Deemed Standard Care for FLT3-ITD AML

Innovent and IASO Bio CAR-T multiple myeloma drug approved

Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel).  FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have…

Continue Reading Innovent and IASO Bio CAR-T multiple myeloma drug approved

Cell free DNA sequencing for precision oncology: technical challenges, clinical opportunities

Dr Mark Murakami Assistant Professor, Medicine, Harvard Medical SchoolInvestigator, Hematologic Neoplasia,Dana-Farber Cancer Institute Host: Dr Katherine Antel Dr Mark Murakami is a hematologist and medical oncologist who specializes in the treatment of patients with leukemia and lymphoma. As an Assistant Professor of Medicine at Harvard Medical School, his research laboratory…

Continue Reading Cell free DNA sequencing for precision oncology: technical challenges, clinical opportunities

Looking Ahead at CAR T-Cell Therapy for R/R Acute Lymphoblastic Leukemia

Less than a decade ago, the big news in treating relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) was the accelerated approval for the bispecific T-cell engager blinatumomab (Blincyto, Amgen), which has since received full approval to treat both adult and pediatric patients with R/R B-cell ALL or those with…

Continue Reading Looking Ahead at CAR T-Cell Therapy for R/R Acute Lymphoblastic Leukemia

A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution.

Abstract PURPOSE: Cell-free DNA (cfDNA) offers a noninvasive approach to monitor cancer. Here we develop a method using whole-exome sequencing (WES) of cfDNA for simultaneously monitoring the full spectrum of cancer treatment outcomes, including minimal residual disease (MRD), recurrence, evolution, and second primary cancers. EXPERIMENTAL DESIGN: Three simulation datasets were…

Continue Reading A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution.

Personalis Sues Foresight Diagnostics Again Alleging Patent Infringement

NEW YORK – Personalis said Monday that it has filed a second patent infringement lawsuit suit against Foresight Diagnostics, seeking injunctive relief and monetary damages, bringing the total number of patents over which Personalis is suing Foresight to seven. Filed in the US District Court for the District of Colorado,…

Continue Reading Personalis Sues Foresight Diagnostics Again Alleging Patent Infringement

Genomic Medicine Market

In numerous ways, genomic medicine is changing healthcare. By analysing an individual’s genetic information, genomic medicine provides personalized illness diagnosis, treatment, and prevention. From identifying genetic risk factors to personalizing pharmaceutical regimens, genomics is crucial to improving patient outcomes. Due to increased demand for precision treatments and advancements in genomic…

Continue Reading Genomic Medicine Market

Analytical considerations for cfDNA biomarker analysis powered by NGS

Powerful liquid biopsy: from multianalytes to ultrasensitive cfDNA analysis A series of three liquid biopsy webinars about how you can get a complete picture by stabilizing and isolating multiple analytes from the same blood draw – to generate insights otherwise undetectable in single analytes. You will learn how to get started…

Continue Reading Analytical considerations for cfDNA biomarker analysis powered by NGS

NGS-MRD Panel Is “Highly Sensitive, Accurate” in AML

A study regarding next-generation sequencing evaluated minimal residual disease in patients with acute myeloid leukemia. Korean researchers have developed a next-generation sequencing (NGS) panel for measuring MRD in patients with acute myeloid leukemia (AML) that they say is highly sensitive, accurate, could be applied in clinical practice to about 78%…

Continue Reading NGS-MRD Panel Is “Highly Sensitive, Accurate” in AML

Managed Care Updates: June 2023

Quality of Life at Diagnosis Predicts Survival in Patients With Lung Cancer Lung cancer carries a substantial symptom burden, and findings from a study published in Clinical Lung Cancer showed that physical and emotional functioning scores within quality-of-life (QOL) questionnaires at diagnosis may help predict survival in patients with lung…

Continue Reading Managed Care Updates: June 2023

High Concordance Seen Between MRD Measurement by MFC and FGT in Infants with KMT2A-r ALL

Pediatric patients with acute lymphoblastic leukemia and have KMT2A rearrangements were evaluated in a recent study published in the British Journal of Haematology. In infants with acute lymphoblastic leukemia (ALL) associated with KMT2A gene rearrangements, measurement of MRD by multicolor flow cytometry (MFC) and by PCR for fusion gene transcripts (FGT) had…

Continue Reading High Concordance Seen Between MRD Measurement by MFC and FGT in Infants with KMT2A-r ALL

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

Amgen has announced the full approval by the US Food and Drug Administration (FDA) of the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab). Blincyto is used to treat adults and children with CD19-positive B-cell precursor acute lymphoblastic leukaemia (B-ALL), who are in their first or second complete remission with…

Continue Reading Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

Week in Review: Quest to offer ctDNA MRD testing | Exact Sciences develops next-gen Cologuard | Detecting Candida auris

Dear LabPulse.com reader: In company news, Quest Diagnostics completed its previously announced acquisition of Haystack Oncology, a developer of minimal-residual disease (MRD) testing technology. Founded in 2021, Haystack has developed a ctDNA-based technology specifically for MRD detection based on 20 years of research and development by Johns Hopkins University. Quest…

Continue Reading Week in Review: Quest to offer ctDNA MRD testing | Exact Sciences develops next-gen Cologuard | Detecting Candida auris

FDA Grants Full Approval to Blinatumomab for MRD+ B-cell Precursor ALL

The FDA has granted regular approval to blinatumomab (Blincyto) for the treatment of adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) in first or second complete remission (CR1, CR2) with minimal residual disease (MRD) of at least 0.1%.1 The agent was initially granted an accelerated approval…

Continue Reading FDA Grants Full Approval to Blinatumomab for MRD+ B-cell Precursor ALL

ASCO 2023: Studies Clarify Role of Immunotherapy in Multiple Myeloma

Four studies presented at the ASCO Annual Meeting 2023 further clarify the role of immunotherapy in the treatment of multiple myeloma (MM). Results from the phase 3 CARTITUDE-4 trial suggested that a chimeric antigen receptor (CAR) T-cell therapy could be used earlier in the course of MM treatment.1 The study…

Continue Reading ASCO 2023: Studies Clarify Role of Immunotherapy in Multiple Myeloma

ASCO Reading Room | Alexander Chehrazi-Raffle, MD, on ctDNA in Metastatic Kidney Cancer

A novel, ultra-sensitive circulating tumor DNA (ctDNA) assay differentiated patients with metastatic kidney cancer who achieved a complete response versus partial response to immunotherapy; it also identified those at risk for disease progression. In a small pilot study published in JCO Precision Oncology, Sumanta K. Pal, MD, of City of…

Continue Reading ASCO Reading Room | Alexander Chehrazi-Raffle, MD, on ctDNA in Metastatic Kidney Cancer

NeoGenomics’ RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics’ RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage FT. MYERS, FL / ACCESSWIRE / June 15, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that its RaDaR® assay, a personalized liquid biopsy for minimal/molecular residual disease (MRD)…

Continue Reading NeoGenomics’ RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

Bioinformatics Scientist 1 – Liquid Biopsy / Collaborations at

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes,…

Continue Reading Bioinformatics Scientist 1 – Liquid Biopsy / Collaborations at

Liquid Biopsy Firms Eye Melanoma for Minimal Residual Disease Testing, Though Questions Remain

NEW YORK – Multiple companies advancing circulating tumor DNA tests have recently increased their attention to melanoma as a clinical target for their minimal residual disease (MRD) assays. The use of liquid biopsy to detect MRD in solid tumor patients has grown over the last several years, with the first…

Continue Reading Liquid Biopsy Firms Eye Melanoma for Minimal Residual Disease Testing, Though Questions Remain

Complete Genomics Unveils New Partnerships at 18th Anniversary

Complete Genomics and Invivoscribe announced in early June that they have entered a global partnership to develop biomarker tests for oncology based on Complete Genomics’ next-generation sequencing platforms. Under the collaboration, Invivoscribe will take part in the development of biomarker tests and associated bioinformatics software using the ultra-high speed DNBSeq-G99RS*…

Continue Reading Complete Genomics Unveils New Partnerships at 18th Anniversary

Pre- or Post-Transplant Xospata Shows Relapse-Free Survival Benefit in AML Group

Maintenance and posttransplant therapy with Xospata (gilteritinib) benefitted half of patients with FLT3-ITD–mutant acute myeloid leukemia (AML) and detectable minimal residual disease (MRD) versus those without detectable MRD, according to findings from a recent trial. MRD refers to a very small number of cancer cells in the body during or…

Continue Reading Pre- or Post-Transplant Xospata Shows Relapse-Free Survival Benefit in AML Group

Complete Genomics Announces Updated Mission and New Partnerships on 18th Anniversary

SAN JOSE, Calif., June 14, 2023 /CNW/ — Complete Genomics, Inc., a pioneering genomics company, today unveiled updated mission/vision statement to reflect renewed ambitions in taking on more for a better world, in celebration of its 18th anniversary. Aligned with this new mission, Complete Genomics announced multiple donations for advancing genomics…

Continue Reading Complete Genomics Announces Updated Mission and New Partnerships on 18th Anniversary

Myriad Partners With MD Anderson to Study MRD Testing in Renal Cell Carcinoma

NEW YORK – Myriad Genetics on Monday said it is starting a new collaboration with MD Anderson Cancer Center to develop Myriad’s minimal residual disease (MR) testing platform as a tool to guide treatment, surveillance, and radiotherapy response in patients with metastatic renal cell carcinoma. The 523-gene Precise MRD test…

Continue Reading Myriad Partners With MD Anderson to Study MRD Testing in Renal Cell Carcinoma

Phase 3 CARTITUDE-4 Results Show Superiority of Cilta-Cel in MM

The first phase 3 results from the CARTITUDE-4 trial of ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in lenalidomide-refractory multiple myeloma (MM) demonstrated the former’s convincing superiority in several key outcomes. Presented during the plenary session at the European Hematology Association 2023 Congress by Hermann Einsele, MD, FRCP of…

Continue Reading Phase 3 CARTITUDE-4 Results Show Superiority of Cilta-Cel in MM

Gracell Biotechnologies Presents Longer-Term Results for

Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among treated patients, all with diffuse large B-cell lymphoma (DLBCL) subtype Data on GC012F for treatment of relapsed/refractory multiple myeloma (RRMM) and donor-derived CAR-T GC007g for treatment of relapsed/refractory B-cell acute…

Continue Reading Gracell Biotechnologies Presents Longer-Term Results for

Phase 3 PhALLCON Trial of Ponatinib and Reduced-Intensity Chemo Shows Promise in Ph+ ALL

An improvement in minimal residual disease (MRD)-negative complete remission (CR) rate was observed with ponatinib (Iclusig) plus reduced-intensity chemotherapy vs imatinib (Gleevec) plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). Findings come from the phase 3 PhALLCON trial (NCT03589326) which were presented at…

Continue Reading Phase 3 PhALLCON Trial of Ponatinib and Reduced-Intensity Chemo Shows Promise in Ph+ ALL

A familial SAMD9 variant present in pediatric myelodysplastic syndrome

Cold Spring Harb Mol Case Stud. 2023 Apr; 9(2): a006256. ,1,2 ,1,2 ,1,2 ,2,3 ,4 and 1,2 Mahvish Q. Rahim 1Pediatric Hematology Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA; 2Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA; April Rahrig 1Pediatric Hematology Oncology,…

Continue Reading A familial SAMD9 variant present in pediatric myelodysplastic syndrome

Personalized Residual Disease Assays Show Promise to Overcome Liquid Biopsy Challenges in Sarcomas

NEW YORK – New findings presented at the American Society of Clinical Oncology in Chicago this week have offered a glimpse into a potential future for blood-based minimal residual disease tests in patients with sarcomas, a challenging application for liquid biopsy technologies due to a lack of recurring or predictable…

Continue Reading Personalized Residual Disease Assays Show Promise to Overcome Liquid Biopsy Challenges in Sarcomas

Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes

The measurable residual disease (MRD) assessment provides an attractive predictor of alloHCT outcomes. Cell-free DNA (cfDNA) has been applied to diagnosis, early detection, and disease burden monitoring in various tumors but its utility as an MRD test in myeloid malignancies has not been systematically evaluated. We sought to determine the…

Continue Reading Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes

CAR-T Therapy May Help Slow Multiple Myeloma Progression

Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting chimeric antigen receptor (CAR) T-cell therapy, may significantly slow or stop the progression of multiple myeloma (MM)  when compared with standard-of-care treatments among patients for whom lenalidomide no longer works, according to new data presented at the ASCO Annual Meeting 2023. The global, phase 3…

Continue Reading CAR-T Therapy May Help Slow Multiple Myeloma Progression

ASCO: Moderna, Merck melanoma vaccine set for phase 3

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase 2b data drop at ASCO. In the study, mRNA-4157 (V940) – which targets dozens of unique tumour-associated antigens or neoantigens…

Continue Reading ASCO: Moderna, Merck melanoma vaccine set for phase 3

Split-dose R-CHOP regimen effective for older adults with newly diagnosed lymphoma

Source/Disclosures Published by: Source: Shah NN, et al. Abstract 7554. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Adaptive Biotechnology and a grant from the Froedtert Foundation supported this study. Shah reports consultant/advisory board roles with, research funding/paid expenses from or stock ownership in Adaptive…

Continue Reading Split-dose R-CHOP regimen effective for older adults with newly diagnosed lymphoma

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical…

Continue Reading Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)